Hogan Lovells helps Novartis expand immunotherapy portfolio with acquisition IFM Tre

Press releases | 02 April 2019

New York, 2 April 2019 – A cross-practice team of lawyers from international law firm Hogan Lovells is advising pharmaceutical company Novartis on its acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC, a privately-held biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition will give Novartis full rights to IFM Tre's portfolio of NLRP3 inhibitors.

The transaction is expected to close during the second quarter of 2019, subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

The Hogan Lovells team was led by New York-based Corporate Transactional partners Adam Golden and Michael Szlamkowicz and senior associate Jeffrey Jay.

An international team of cross-practice Hogan Lovells lawyers also worked on the transaction:

In New York: Employment partner Michael DeLarco and associate Mitra Anoushiravani; IPMT partners Simon Roberts and Jason Leonard; Corporate Transactional senior associate Thabisa Lane, and associates Katherine Jeffery and Katie Haines; and Tax associate Catherine Chen.

In Washington D. C.: Global Regulatory partners Leigh Oliver and Brian Curran, senior associate Lauren Battaglia, and associate Zachary Alvarez; Tax partners Carin Carithers and Christine Lane.

In London: Tax partner Karen Hughes and senior associate Tom Eyre-Brook.

About Hogan Lovells

Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.

"Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP. For more information, see www.hoganlovells.com.